<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412645</url>
  </required_header>
  <id_info>
    <org_study_id>LIRMOI</org_study_id>
    <nct_id>NCT01412645</nct_id>
  </id_info>
  <brief_title>Long-term Investigation of Resveratrol in Obesity</brief_title>
  <acronym>LIRMOI</acronym>
  <official_title>Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Denmark Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate potential metabolic effects of resveratrol in men
      with metabolic syndrome(otherwise healthy).

      The investigators hypothesize that resveratrol has an anti-inflammatory effect, and will
      increase insulin sensitivity, change the fat- and sugar-metabolism, and down-regulate
      bone-turnover.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be done in a collaboration between two PhD students, who focus on effects in
      adipose- and muscle- tissue, and bone tissue respectively.

      The investigators will look at changes in

        -  inflammation-markers

        -  biochemical markers of fat- and sugar-metabolism

        -  gene-expression in fat- and muscle-tissue

        -  body composition (DXA (whole body) and MR spectroscopy)

        -  biochemical markers of bone-metabolism

        -  Bone Mineral Density (DXA scans)

        -  bone structure (QCT)

        -  gene-expression and cytokines in bone marrow

      Some of the volunteers will have their insulin sensitivity measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from Baseline in markers of inflammation (hs-CRP) in blood after 4 months of treatment with either resveratrol or placebo</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Obesity</condition>
  <condition>Inflammation</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or
1 placebo 2 times daily for 4 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>High-dose Resveratrol</arm_group_label>
    <arm_group_label>Low-dose Resveratrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  30-60 years old

          -  Metabolic Syndrome

          -  Written informed consent

        Exclusion Criteria:

          -  Diabetes, thyroid or parathyroid disease, hypogonadism

          -  Treatment-requiring osteoporosis

          -  Heart, liver or kidney disease

          -  Present or previous malignancy

          -  MR contraindication

          -  Alcohol dependency

          -  Weight &gt; 130 kilograms
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steen B Pedersen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Institute, Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.lirmoi.com</url>
    <description>Official web page for the LIRMOI projekt, background info and contact</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>July 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Bone turnover</keyword>
  <keyword>Ectopic fat accumulation</keyword>
  <keyword>Resveratrol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
